BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory


Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day.

A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen target sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

Posts Mentioning This Company

AI Drug Discovery Financing Roundup: Unlearn.AI, Iktos, DenovAI, and More

The role of artificial intelligence (AI) in drug discovery is rapidly increasing, since it was shown to be able to expedite R&D process, reduce costs, and provide novel research insights via big data and pattern recognition. AI has found numerous use cases in drug discovery, including target discovery, hit identification, …